SK Biopharm opens New Jersey hub to help Korean biotech firms enter US market

SK Biopharm has thrown open the infrastructure of its US subsidiary to launch a global co-growth platform designed to help promising South Korean biotech ventures and startups establish themselves in the North American market.

The company announced Tuesday that it opened SK Life Science LinX, an open-innovation space, on June 5 at SK Life Science, its New Jersey subsidiary, to lead the US market entry and local growth of South Korean pharmaceutical and biotech firms.

The facility spans 528 square meters (160 pyeong, where 1 pyeong equals 3.3 square meters) and is equipped with infrastructure optimized for conducting business in the United States — including 396 square meters of shared common space for visitor networking, 10 private offices and conference rooms. The "X" in the name stands for eXchange, eXpansion and eXploration. The space is intended to serve as a core "K-bio bridge" connecting Asia's strong research and development capabilities with the advanced market expertise of North America.

The opening ceremony on June 5 drew roughly 100 South Korean and American business and government figures, including SK Biopharm President Lee Dong-hoon and other senior executives, KOTRA New York Trade Center Director Kim Rak-gon, Korean-American Society of Bio-Pharmaceuticals New Jersey-New York chapter President Kang Min-seok, Korea Health Industry Development Institute US office Director Kim Hyun-chul, and newly appointed Consul General of Korea in New York Kim Sang-ho. At the event, SK Biopharm, KOTRA and KASBP signed a three-way MOU committing to mutual cooperation to put the platform into full operation.

Inside LinX, KOTRA will lead a biotech cooperation consortium running the "K-Bio Global Innovation LinX" program. Station C, a regional startup brand operated by the Korea Health Industry Development Institute and Hallym University, has confirmed its participation, and discussions with additional domestic institutions are ongoing.

The consortium plans to offer companies based at LinX a range of specialized programs to minimize the risks of entering the US market — covering initial settlement support, legal and patent advisory services, and connections to local venture capital firms and investors. The KASBP New Jersey-New York chapter will use the space as a base to hold regular academic symposiums and seminars, bridging global top-tier talent with South Korean companies.

SK Biopharm said the opening of LinX gives concrete, global expression to the company's long-emphasized ESG management philosophy by building a co-growth ecosystem. The company plans to begin recruiting its first cohort of resident companies this month, targeting promising South Korean biotech firms and startups seeking to enter the US market.